SMNR Semnur Pharmaceuticals, Inc.

CIK 0001913577 46 ready 8-Ks latest July 7, 2026, 10:38 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 46

Latest filing July 7, 2026, 10:38 AM ET

Top materiality 0.90

Event mix other_material ×31 · m_and_a ×11 · regulatory ×2

Sentiment 4 pos · 6 neg · 36 neu

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for SMNR

Highest-materiality recent filing

Denali SPAC enters $2.5B stock merger with Semnur Pharmaceuticals

September 5, 2024, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 7.01 item 9.01

Equity value of $2.5B; consideration payable in Denali (New Semnur) common shares.
Scilex (Semnur parent) buys 500k Denali Class B shares for $2M cash and 300k Scilex shares.

Read filing →

July 7, 2026, 10:38 AM ET other material materiality 0.75 positive item 1.01 item 3.02 item 7.01 item 9.01

Semnur signs binding term sheet for $100M strategic investment from iHolding Group at $10/share

iHolding to purchase $100M of newly issued common stock at $10/share (~10M shares).
April 23, 2026, 7:59 PM ET other material materiality 0.75 negative item 1.02 ◈ Material Agreements ×2

Semnur terminates two material financing agreements totaling $120M in potential proceeds

Terminated PIPE SPA with JW Capital Securities Ltd for 1.25M shares at $16/share ($20M).
March 17, 2026, 7:59 PM ET leadership materiality 0.75 neutral item 5.02 item 9.01

CEO Jaisim Shah retires; Henry Ji appointed CEO and President; Stephen Ma named COO

Jaisim Shah resigned as CEO, President, and director effective March 13, 2026; retirement not due to any disagreement.
September 26, 2025, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 2.01 item 9.01 item 5.02 item 3.02 item 4.01 item 2.03 item 3.03 item 8.01 item 5.01 item 5.03 item 5.05 item 5.06 item 7.01 ◈ Governance Changes ×4◈ Debt Financings ×2◈ M&A Transactions ×2

Semnur completes de-SPAC merger with Denali; trades under SMNR on OTCQB

Business combination closed Sept 22, 2025; Legacy Semnur becomes wholly owned subsidiary of New Semnur.
September 4, 2025, 7:59 PM ET other material materiality 0.70 neutral item 5.07

Shareholders approve merger with Semnur Pharmaceuticals at September 3 meeting

All 9 proposals, including business combination with Semnur, approved by 94.08% quorum.
August 22, 2025, 7:59 PM ET M&A materiality 0.70 positive item 1.01 item 3.02 item 9.01

Denali Capital enters $20M PIPE at $16/share and 12M share escrow for Semnur merger

PIPE purchase of 1.25M shares at $16.00 each for $20M total from a single purchaser.
August 11, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Denali Capital extends SPAC deadline to Sep 11, 2025 with $874.78 trust deposit

Deposited $874.78 into trust account to extend business combination deadline by one month.
July 28, 2025, 7:59 PM ET M&A materiality 0.60 neutral item 1.01 item 9.01

Denali Capital Acquisition Corp. enters Amendment No. 2 to Merger Agreement with Semnur Pharmaceuticals

Amendment No. 2 signed on July 22, 2025 modifies Exchange Ratio and Merger Consideration definitions.
April 22, 2025, 7:59 PM ET M&A materiality 0.65 neutral item 1.01 item 9.01

Denali Capital amends merger pact with Semnur; extends deadline to Sept 2025, addresses Nasdaq delisting

Amendment allows Denali to extend business combination deadline to Dec 11, 2025, or later if mutually agreed.
April 16, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07 item 8.01 item 9.01

Denali Capital shareholders approve extension to Dec 2025; ~708K shares redeemed for ~$8.6M

Shareholders voted to extend business combination deadline to December 11, 2025, via up to 8 monthly extensions.
April 9, 2025, 7:59 PM ET other material materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

Denali Capital receives Nasdaq delisting determination; must appeal by April 9 or face suspension

On April 2, 2025, Nasdaq staff determined Denali failed to meet MVLS, total assets, and public float rules.
February 11, 2025, 6:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Denali Capital Acquisition Corp. Extends Business Combination Deadline to March 11, 2025

Deposited $15,036.74 into trust account to extend deadline for completing a business combination by one month.
October 7, 2024, 7:59 PM ET regulatory materiality 0.65 negative item 3.01

Denali Capital Acquisition receives Nasdaq deficiency notice for non-compliance with listing rules

Nasdaq notified Denali on Oct 2, 2024 of non-compliance with MVLS ($50M minimum) and Total Assets rules for Nasdaq Global Market.
September 5, 2024, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 7.01 item 9.01

Denali SPAC enters $2.5B stock merger with Semnur Pharmaceuticals

Equity value of $2.5B; consideration payable in Denali (New Semnur) common shares.
August 9, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 2.03 item 8.01 item 9.01

Denali Capital extends business combination deadline to Sep 11 via $180K Scilex note

Deposited $15,036.74 into trust to extend deadline to Sep 11, 2024 from Aug 11.
July 10, 2024, 7:59 PM ET other material materiality 0.80 negative item 1.01 item 2.03 item 5.03 item 5.07 item 7.01 item 9.01

Denali Capital shareholders approve extension to Apr 2025; 3.8M shares redeemed for ~$43.4M

Shareholders approved extension of business combination deadline from July 11, 2024 to April 11, 2025 via monthly extensions.
July 5, 2024, 7:59 PM ET M&A materiality 0.70 neutral item 7.01 item 9.01

Denali Capital SPAC signs LOI to combine with Semnur Pharma at up to $2B valuation

Pre-transaction equity value of Semnur up to $2.0B, subject to third-party fairness opinion adjustment.
June 27, 2024, 7:59 PM ET other material materiality 0.85 negative item 1.02 item 7.01 item 9.01

Denali Capital terminates business combination with Longevity Biomedical; SPAC seeks new target

Merger agreement terminated effective June 26, 2024, by mutual agreement of Denali and Longevity Biomedical.
February 27, 2024, 6:59 PM ET regulatory materiality 0.65 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Denali Capital receives Nasdaq deficiency notice for MVLS below $50M; 180 days to comply

Nasdaq letter on Feb 22, 2024 cites MVLS below $50M for 30 consecutive days, violating Rule 5450(b)(2)(A).
January 10, 2024, 6:59 PM ET M&A materiality 0.75 neutral item 5.07 item 9.01

Denali Capital shareholders approve merger with Longevity Biomedical; 4.44M shares redeemed

Shareholders approved all proposals: Business Combination, Merger, Share Capital, Organizational Documents, Governance, and Incentive Plan.
October 11, 2023, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 2.03 item 5.03 item 5.07 item 7.01 item 9.01 ◈ Shareholder Votes ×3◈ Debt Financings◈ Governance Changes◈ Material Agreements

Denali Capital extension approved, ~$40.5M redeemed, up to $450k promissory note

Shareholders approved extension to July 11, 2024 with monthly $50k deposits; $50k deposited for first month.
August 30, 2023, 7:59 PM ET M&A materiality 0.70 positive item 8.01

Longevity Biomedical waives $30M minimum cash condition for Denali merger

Longevity irrevocably waived the $30M minimum cash condition in the merger agreement with Denali Capital Acquisition Corp.
August 28, 2023, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements

Denali SPAC Holdco secures $18M Series A Preferred investment from FutureTech Capital for business combination

FutureTech Capital commits to purchase 1.8M shares of Series A Convertible Preferred Stock at $10/share ($18M total).
January 26, 2023, 6:59 PM ET M&A materiality 0.90 neutral item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Denali Capital Acquisition Corp. enters merger agreement with Longevity Biomedical

Denali entered into a merger agreement with Longevity Biomedical, Inc. on Jan 25, 2023, with a total enterprise value of $128 million.
January 26, 2023, 6:59 PM ET M&A materiality 0.75 neutral item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Denali Capital SPAC to merge with Longevity Biomedical in deal valued at $128M, listing as LBIO

Merger consideration of $128M payable in shares of New PubCo common stock at $10.00 per share.
October 19, 2022, 7:59 PM ET other material materiality 0.60 neutral item 4.01 item 9.01

Denali Capital Acquisition Corp replaces auditor; prior audit flagged going concern

Dismissed Friedman LLP on Oct 14, 2022; appointed Marcum LLP effective immediately.
April 12, 2022, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01 ◈ executive_change ×3

Denali Capital Acquisition Corp. prices $75M IPO, upsized to $82.5M including over-allotment

IPO of 7,500,000 units at $10.00/unit, plus over-allotment of 750,000 units, for total 8,250,000 units.

Executive changes

Appointed

Huifeng Chang

Director

SMNR · Semnur Pharmaceuticals, Inc.

Effective: 2022-04-06
Filed: April 12, 2022, 7:59 PM ET

Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.

Appointed

Jim Mao

Director

SMNR · Semnur Pharmaceuticals, Inc.

Effective: 2022-04-06
Filed: April 12, 2022, 7:59 PM ET

Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.

Appointed

Kevin D. Vassily

Director

SMNR · Semnur Pharmaceuticals, Inc.

Effective: 2022-04-06
Filed: April 12, 2022, 7:59 PM ET

Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

4 positive 6 negative 36 neutral

source · SMNR on sec.gov